Company Overview and News

 
Calls for calm after legal action lodged against of Spirit of Tasmania

2018-08-29 abc.net.au
Legal action against a Tasmanian ferry owner over the deaths of 16 prized polo ponies should not prevent the equine industry from having confidence in the TT-Line, a horse transporter says.
QUB

 
Polo pony owner makes $740,000 compo claim over Tasmania ferry deaths

2018-08-29 smh.com.au
The owner of some of the 16 polo ponies who died in transit from Devonport to Melbourne is claiming $739,000 in damages from the Spirit of Tasmania's operators.
QUB

 
Dividends are nice but there won't be any if the company shrinks to zero

2018-08-28 theage.com.au
It’s raining dividends in corporate Australia and most shareholders will be rejoicing while raising their umbrellas.
MDBKY MPL MDBPF QUB

 
Dividends are nice but there won't be any if the company shrinks to zero

2018-08-28 smh.com.au
It’s raining dividends in corporate Australia and most shareholders will be rejoicing while raising their umbrellas.
MDBKY MPL MDBPF QUB

 
Spirit of Tasmania owners sued over polo pony deaths

2018-08-28 abc.net.au
The Spirit of Tasmania operator TT-Line is being sued for negligence over the death of 16 prized polo ponies that crossed Bass Strait in January.
QUB

2
Top companies 'failing' on gender pay gap face investor revolt

2018-07-23 theage.com.au
Investors could take stronger action to force listed companies to address the gender pay gap – including protest votes against re-election of board members and executive remuneration – according to the Australasian Centre for Corporate Responsibility (ACCR) which found that more than one quarter of ASX100 companies did not have a remuneration policy that explicitly covered gender pay equity.
JBHHY RMYHY JHIUF EVN MDBPF LGTHY SYDDF CIM SYD QUB GMG CAHPF RMSYF HNORY JHX TPPTY TPM JHX JBH MDBKY MPL TPGTF RHC HVN LGTHF BTT

2
Top companies 'failing' on gender pay gap face investor revolt

2018-07-23 smh.com.au
Investors could take stronger action to force listed companies to address the gender pay gap – including protest votes against re-election of board members and executive remuneration – according to the Australasian Centre for Corporate Responsibility (ACCR) which found that more than one quarter of ASX100 companies did not have a remuneration policy that explicitly covered gender pay equity.
JBHHY RMYHY JHIUF EVN MDBPF LGTHY SYDDF CIM SYD QUB GMG CAHPF RMSYF HNORY JHX TPPTY TPM JHX JBH MDBKY MPL TPGTF RHC HVN LGTHF BTT

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...